References
- O’Brien ME, Ciuleanu TE, Tsekov H et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J. Clin. Oncol.24, 5441–5447 (2006).
- Eckardt JR, von Pawel J, Papai Z et al. Open-label, multicenter, randomized, Phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J. Clin. Oncol.24, 2044–2051 (2006).
- von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol.17, 658–667 (1999).
- Garst J, Buller R, Lane S, Crawford J. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clin. Lung Cancer7, 190–196 (2005).
- Huber RM, Reck M, Gosse H et al. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur. Respir. J.27, 1183–1189 (2006).
- Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol.10, 1225–1229 (1992).
- Onoda S, Masuda N, Seto T et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J. Clin. Oncol.24, 5448–5453 (2006).
- Kaira K, Sunaga N, Tomizawa Y et al. A Phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer69, 99–104 (2010).
- Ettinger DS, Jotte R, Lorigan P et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J. Clin. Oncol.28, 2598–2603 (2010).
- Inoue A, Sugawara S, Yamazaki K et al. Randomized Phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J. Clin. Oncol.26, 5401–5406 (2008).
- Jotte R, Conkling P, Reynolds C et al. Randomized Phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J. Clin. Oncol.29(3), 287–293 (2011).
- Smit EF, Fokkema E, Biesma B et al. A Phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br. J. Cancer77, 347–351 (1998).
- Yamamoto N, Tsurutani J, Yoshimura N et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res.26, 777–781 (2006).
- Smyth JF, Smith IE, Sessa C et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur. J. Cancer30, 1058–1060 (1994).
- Furuse K, Kubota K, Kawahara M et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology53, 169–172 (1996).
- Jassem J, Karnicka-Młodkowska H, van Pottelsberghe C et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur. J. Cancer29, 1720–1722 (1993).
- Schmittel A, Knödler M, Hortig P, Schulze K, Thiel E, Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer55, 109–113 (2007).
- Masters GA, Declerck L, Blanke C et al.; Eastern Cooperative Oncology Group. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J. Clin. Oncol.21, 1550–1555 (2003).
- Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur. J. Cancer Clin. Oncol.23, 1697–1699 (1987).
- Masuda N, Matsui K, Negoro S et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol.16, 3329–3334 (1998).
- Goto K, Sekine I, Nishiwaki Y et al. Multi-institutional Phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br. J. Cancer91, 659–665 (2004).
- Fujita A, Takabatake H, Tagaki S, Sekine K. Combination of cisplatin, ifosfamide, and irinotecan with rhG–CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology59, 105–109 (2000).
- Groen HJ, Fokkema E, Biesma B et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J. Clin. Oncol.17, 927–932 (1999).